about
Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescentsUse of Therapeutic Drug Monitoring, Electronic Health Record Data, and Pharmacokinetic Modeling to Determine the Therapeutic Index of Phenytoin and Lamotrigine.Therapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure-Response Relationships in Renal Transplant PatientsPharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults.Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage AdjustmentsAdvances in pediatric pharmacology, therapeutics, and toxicology.Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency.Vancomycin cerebrospinal fluid pharmacokinetics in children with cerebral ventricular shunt infections.Lessons learned in pediatric clinical research to evaluate safe and effective use of drugs in pregnancy.Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation.Drug Dosing and Pharmacokinetics in Children With Obesity: A Systematic ReviewPharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Clinical Pharmacology Studies in Critically Ill Children.Pharmacologic studies in vulnerable populations: Using the pediatric experience.Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data.Oral adherence monitoring using a breath test to supplement highly active antiretroviral therapy.Solithromycin Pharmacokinetics in Plasma and Dried Blood Spots and Safety in Adolescents.Clindamycin Pharmacokinetics and Safety in Preterm and Term InfantsAn opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants.Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.Improving Pediatric Protein Binding Estimates: An Evaluation of α1-Acid Glycoprotein Maturation in Healthy and Infected Subjects.Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton MyastheniaExposure Matching for Extrapolation of Efficacy in Pediatric Drug Development.Use of Population Pharmacokinetics and Electronic Health Records to Assess Piperacillin-Tazobactam Safety in Infants.Therapeutic Index Estimation of Antiepileptic Drugs: A Systematic Literature Review Approach.Exposure Matching of Pediatric Anti-infective Drugs: Review of Drugs Submitted to the Food and Drug Administration for Pediatric Approval.Pharmacokinetics of Clindamycin in Obese and Nonobese Children.Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age.External Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models.Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid.Association between oral sildenafil dosing, predicted exposure, and systemic hypotension in hospitalised infants.Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children.Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation.Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.Pharmacokinetics of Ceftaroline in a Preterm Infant With Methicillin-Resistant Staphylococcus Aureus Pneumonia.Advances in Pediatric Pharmacology, Therapeutics, and Toxicology.External Evaluation of a Gentamicin Infant Population Pharmacokinetic Model Using Data from a National Electronic Health Record DatabaseChallenges and Solutions for Future Pharmacy Practice in the Era of Precision MedicinePediatric Drug-Drug Interaction Studies: Barriers and Opportunities
P50
Q30832465-8552796F-5050-4DB1-8A6F-0E7A61AE22FEQ31138033-FB1C8DC3-F798-4E38-8A6F-74F0FF0A72E5Q33432698-A68C8CE1-582A-45E4-9983-55A5F9A6050AQ33657212-0B22B6BE-C414-4BC1-AAAF-6C3AA2D848A4Q33729768-E8924B87-A783-433A-AD9B-5F522B44F675Q33763177-3B4E97B9-9071-4EF9-BF09-EE20AB332EA9Q33998667-C538CA1C-4A9C-4930-A0FF-4A8E73924D83Q34145171-B97EC5C6-DE5E-4F9B-A94B-F83EAB635DCDQ34403094-D87D1499-9C7B-45FE-B8BD-6B9F58C6031EQ35214105-4F93ADA6-F03D-4E51-AB16-6D0BBB71A7AAQ35746253-7550B94C-F3AE-4A02-A87C-990EEFDD076BQ35828378-EA37654D-7EDD-4F08-B7C9-A6B337E039D4Q36083619-F370648D-166F-4AA6-B2BF-CE4EBF26D94EQ36120465-772FE0E6-4CE6-4605-BC46-813CF9AF072EQ36235896-99455206-0FD2-4395-BF20-221B2D4236B5Q36307045-D0A49C11-9642-4916-835E-FD52E7257005Q36545120-3BA6D629-4912-4CBE-AAA3-F123840B1C9AQ36730079-D8046180-5D0E-4B8E-BD98-5A9880E1C310Q36887756-430181EE-09FF-4727-834D-9846548BDF4BQ37212142-E25B1E1B-AC7A-48B1-9375-2CB5C5C4CE5BQ37426165-91811A65-20AF-49FE-A136-9B1A2F851EC2Q38639379-8AB3052D-74B7-40AF-AA3F-417613EB8B9CQ38721390-6741D855-8DD8-4046-AD1E-EA5137B38D2DQ38797102-BC2C5D18-A60F-4C07-AC9C-564F0C181C20Q38836711-58A7D5A7-164C-4ECC-A528-AE94D095E667Q38840677-DB5C637C-5B15-4F86-82EE-09FA4710D202Q38846523-6C32A8C3-DAB2-4E47-9E50-112CAB8D3155Q38991202-2E9756D4-AB64-49EB-83C3-CD13DD45C193Q39036174-FE39A85F-9A6E-43F6-BF70-1522308EAE85Q46406734-6C676BC1-80C0-4999-AA31-DED584004ED7Q47134454-DA02C77D-3AE3-4DE2-8D62-BA1CA160C01BQ47138116-D47DB747-9C23-459F-99D4-9EB85E5376A5Q47689257-0752A426-5F7C-4DCF-A626-FC8568462A5FQ47982489-44D7C827-205E-4D3A-9869-963D8C6C35B2Q49171317-377F8473-BA44-4F1F-B160-6AC65AFCF2D9Q50089893-C82B2459-798B-4516-8478-9850405799CEQ54194778-800D4666-E67F-414F-85AB-75ED4B3ED485Q56888516-14B2C36E-37F8-4722-954C-F3635F914507Q57171377-5AE6B9C4-0437-493C-A0CC-E90BC7093A1DQ58554405-F1F4EA7D-D960-47E4-9178-F867F38158A7
P50
description
researcher (ORCID 0000-0001-5522-5686)
@en
wetenschapper
@nl
name
Daniel Gonzalez
@en
Daniel Gonzalez
@nl
type
label
Daniel Gonzalez
@en
Daniel Gonzalez
@nl
prefLabel
Daniel Gonzalez
@en
Daniel Gonzalez
@nl
P31
P496
0000-0001-5522-5686